Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas

Gastroenterology

Volumn 153, Issue 4, 2017, Pages 1107-1119.e10

  Zhou, Guoying ^a   Sprengers, Dave ^a   Boor, Patrick P C ^a   Doukas, Michail ^a   Schutz, Hannah ^a   Mancham, Shanta ^a   Pedroza Gonzalez, Alexander ^b   Polak, Wojciech G ^a   de Jonge, Jeroen ^a   Gaspersz, Marcia ^a   Dong, Haidong ^c   Thielemans, Kris ^d   Pan, Qiuwei ^a   IJzermans, Jan N M ^b   Bruno, Marco J ^a   Kwekkeboom, Jaap ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c MAYO GRADUATE SCHOOL   (United States)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Galectin 9; GPC3; Immunotherapy; MAGEC2

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GRANZYME B; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; LYMPHOCYTE ACTIVATING 3 PROTEIN; LYMPHOCYTE RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CD223 ANTIGEN; CTLA4 PROTEIN, HUMAN; HAVCR2 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PDCD1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CANCER PATIENT; CANCER SURGERY; CANCER TISSUE; CASE CONTROL STUDY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TISSUE; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; CELL CULTURE; CELL PROLIFERATION; COCULTURE; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; PROCEDURES; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; UPREGULATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CTLA-4 ANTIGEN; CYTOKINES; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; UP-REGULATION;

EID: 85031662977     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.06.017     Document Type: Article

References (59)

1. Ferlay, J., Soerjomataram, I., Dikshit, R., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136 (2015), E359–E386.
2. Mazzanti, R., Gramantieri, L., Bolondi, L., Hepatocellular carcinoma: epidemiology and clinical aspects. Mol Aspects Med 29 (2008), 130–143.
3. El-Serag, H.B., Marrero, J.A., Rudolph, L., et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134 (2008), 1752–1763.
4. Gao, Q., Qiu, S.J., Fan, J., et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25 (2007), 2586–2593.
5. Chew, V., Tow, C., Teo, M., et al. Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol 52 (2010), 370–379.
6. Pedroza-Gonzalez, A., Verhoef, C., Ijzermans, J.N., et al. Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology 57 (2013), 183–194.
7. Pedroza-Gonzalez, A., Zhou, G., Singh, S.P., et al. GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo. Oncoimmunology, 4, 2015, e1051297.
8. Pedroza-Gonzalez, A., Zhou, G., Vargas-Mendez, E., et al. Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors. Oncoimmunology, 4, 2015, e1008355.
9. Fourcade, J., Sun, Z., Pagliano, O., et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 72 (2012), 887–896.
10. Wherry, E.J., T cell exhaustion. Nat Immunol 12 (2011), 492–499.
11. Baitsch, L., Baumgaertner, P., Devevre, E., et al. Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. J Clin Invest 121 (2011), 2350–2360.
12. Nguyen, L.T., Ohashi, P.S., Clinical blockade of PD1 and LAG3—potential mechanisms of action. Nat Rev Immunol 15 (2015), 45–56.
13. Brahmer, J.R., Tykodi, S.S., Chow, L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 (2012), 2455–2465.
14. Topalian, S.L., Hodi, F.S., Brahmer, J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
15. Borghaei, H., Paz-Ares, L., Horn, L., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
16. Hamid, O., Robert, C., Daud, A., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369 (2013), 134–144.
17. Topalian, S.L., Sznol, M., McDermott, D.F., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32 (2014), 1020–1030.
18. Wolchok, J.D., Kluger, H., Callahan, M.K., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369 (2013), 122–133.
19. Flecken, T., Schmidt, N., Hild, S., et al. Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. Hepatology 59 (2014), 1415–1426.
20. Kuang, D.M., Zhao, Q., Peng, C., et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 206 (2009), 1327–1337.
21. Wu, K., Kryczek, I., Chen, L., et al. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res 69 (2009), 8067–8075.
22. Zhao, Q., Xiao, X., Wu, Y., et al. Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients. Eur J Immunol 41 (2011), 2314–2322.
23. Li, H., Wu, K., Tao, K., et al. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology 56 (2012), 1342–1351.
24. Sideras, K., Bots, S.J., Biermann, K., et al. Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area. Br J Cancer 112 (2015), 1911–1920.
25. Sideras, K., Biermann, K., Verheij, J., et al. PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma. Oncoimmunology, 6, 2017, e1273309.
26. Shi, X.L., de Mare-Bredemeijer, E.L., Tapirdamaz, O., et al. CMV primary infection is associated with donor-specific T cell hyporesponsiveness and fewer late acute rejections after liver transplantation. Am J Transplant 15 (2015), 2431–2442.
27. Tapirdamaz, O., Mancham, S., van der Laan, L.J., et al. Detailed kinetics of the direct allo-response in human liver transplant recipients: new insights from an optimized assay. PLoS One, 5, 2010, e14452.
28. Bonehill, A., Heirman, C., Tuyaerts, S., et al. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol 172 (2004), 6649–6657.
29. Yoshikawa, T., Nakatsugawa, M., Suzuki, S., et al. HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells. Cancer Sci 102 (2011), 918–925.
30. Straetemans, T., van Brakel, M., van Steenbergen, S., et al. TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets. Clin Dev Immunol, 2012, 2012, 586314.
31. Shi, F., Shi, M., Zeng, Z., et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 128 (2011), 887–896.
32. Li, F.J., Zhang, Y., Jin, G.X., et al. Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients. Immunol Lett 150 (2013), 116–122.
33. Gros, A., Robbins, P.F., Yao, X., et al. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J Clin Invest 124 (2014), 2246–2259.
34. Xu, Y., Li, H., Gao, R.L., et al. Expansion of interferon-gamma-producing multifunctional CD4+ T-cells and dysfunctional CD8+ T-cells by glypican-3 peptide library in hepatocellular carcinoma patients. Clin Immunol 139 (2011), 302–313.
35. Sawada, Y., Yoshikawa, T., Shimomura, M., et al. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. Int J Oncol 46 (2015), 28–36.
36. Baitsch, L., Legat, A., Barba, L., et al. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One, 7, 2012, e30852.
37. Legat, A., Speiser, D.E., Pircher, H., et al. Inhibitory receptor expression depends more dominantly on differentiation and activation than “exhaustion” of human CD8 T cells. Front Immunol, 4, 2013, 455.
38. Fourcade, J., Sun, Z., Benallaoua, M., et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 207 (2010), 2175–2186.
39. Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 107 (2010), 7875–7880.
40. Van Nuffel, A.M., Tuyaerts, S., Benteyn, D., et al. Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens. J Immunol Methods 377 (2012), 23–36.
41. Sangro, B., Gomez-Martin, C., de la Mata, M., et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 59 (2013), 81–88.
42. El-Khoueiry, A.B., Sangro, B., Yau, T., et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389 (2017), 2492–2502.
43. Germeau, C., Ma, W., Schiavetti, F., et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 201 (2005), 241–248.
44. Dolton, G., Lissina, A., Skowera, A., et al. Comparison of peptide-major histocompatibility complex tetramers and dextramers for the identification of antigen-specific T cells. Clin Exp Immunol 177 (2014), 47–63.
45. Lissina, A., Ladell, K., Skowera, A., et al. Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J Immunol Methods 340 (2009), 11–24.
46. Wooldridge, L., Lissina, A., Cole, D.K., et al. Tricks with tetramers: how to get the most from multimeric peptide-MHC. Immunology 126 (2009), 147–164.
47. Dong, H., Strome, S.E., Salomao, D.R., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8 (2002), 793–800.
48. da Silva, I.P., Gallois, A., Jimenez-Baranda, S., et al. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res 2 (2014), 410–422.
49. Fourcade, J., Sun, Z., Benallaoua, M., et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 207 (2010), 2175–2186.
50. Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 107 (2010), 7875–7880.
51. Boor, P.P., Metselaar, H.J., Jonge, S., et al. Human plasmacytoid dendritic cells induce CD8(+) LAG-3(+) Foxp3(+) CTLA-4(+) regulatory T cells that suppress allo-reactive memory T cells. Eur J Immunol 41 (2011), 1663–1674.
52. Yoshikawa, T., Nakatsugawa, M., Suzuki, S., et al. HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells. Cancer Sci 102 (2011), 918–925.
53. Flecken, T., Schmidt, N., Hild, S., et al. Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. Hepatology 59 (2014), 1415–1426.
54. O'Beirne, J., Farzaneh, F., Harrison, P.M., Generation of functional CD8+ T cells by human dendritic cells expressing glypican-3 epitopes. J Exp Clin Cancer Res, 29, 2010, 48.
55. Germeau, C., Ma, W., Schiavetti, F., et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 201 (2005), 241–248.
56. Tapirdamaz, O., Mancham, S., van der Laan, L.J., et al. Detailed kinetics of the direct allo-response in human liver transplant recipients: new insights from an optimized assay. PLoS One, 5, 2010, e14452.
57. von Bergwelt-Baildon, M.S., Vonderheide, R.H., Maecker, B., et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 99 (2002), 3319–3325.
58. Coughlin, C.M., Vance, B.A., Grupp, S.A., et al. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 103 (2004), 2046–2054.
59. Straetemans, T., van Brakel, M., van Steenbergen, S., et al. TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets. Clin Dev Immunol, 2012, 2012, 586314.